Publication Topic

Dean R, Arjunji R, Awano H, Igarash A^, Tanaka A, Jensen IS, Cyr PL et al. Cost-effectiveness of onasemnogene abeparvocec (ZOLGENSMA) for spinal muscular atrophy type 1 against nusinersen in Japan. ISPOR 25th Annual International Meeting, Orlando FL, 2020.

Sacks NC, Healey B, Cyr PL, Graham R. Economic burden of X-linked myotubular myopathy (XLMTM) by ventilation status. ISPOR 25th Annual International Meeting, Orlando FL, 2020.

Jensen IS, Hathway J, Cyr PL, Gauden D, Gardiner P. 2020. Cost–consequence analysis of ¹⁸F-fluciclovine for the staging of recurrent prostate cancer. J Mark Access Health Pol 8(1):1749362; doi: 10.1080/20016689.2020.1749362.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Jena A, et al. 2020. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives. J Med Econ 23(6):581-592; doi: 10.1080/13696998.2020.1730123.

Dean R, Miller B, Arjunji R, Feltner DE, Sproule DM, Jensen I, Dabbous O. Cost-utility analysis of single dose gene-replacement therapy for spinal muscular atrophy type 1 compared to chronic nusinersen treatment in Japan. Abstract PMU36, ISPOR 2020.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al. Budget impact of improving adherence to colorectal cancer screening. Abstract PCN148, ISPOR 2020.

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al. The impact of increasing mt-sDNA use among colorectal cancer screeners in a US employer population. Abstract PCN145, ISPOR 2020.

Sacks NC, Healey B, Cyr PL, Batt K, Henig NR. The economic burden of bronchiolitis obliterans syndrome (BOS) in allogenic hematopoietic stem cell transplant (alloHSCT) patients with Medicare coverage. Poster presentation, ISPOR 25th Annual International Meeting, Orlando, FL, May 2020.

Frankenfeld CL, Menon N, Leslie TF. 2020. Racial disparities in colorectal cancer time-to-treatment and survival time for colorectal tumors and diagnosing hospital cancer-related diagnostic and treatment capabilities. Cancer Epidemiol 65(Apr):101684; doi: 10.1016/j.canep.2020.101684. PMID: 32058312.

Busse LW, Nicholson G, Nordyke RJ, Lee C-H, Zeng F, Albertson TE. 2020. Angiotensin II for the treatment of distributive shock in the intensive care unit: A US cost-effectiveness analysis. Intl J Tech Assess Health Care 36(2):145-151; doi: 10.1017/S0266462320000082. PMID: 32114996.